Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **cell–extracellular matrix (ECM) interface** is the specialized region where cells physically connect to the surrounding ECM via diverse cell-surface receptor families, most prominently the integrins[2][3][4][5][9]. This interface is a dynamic hub crucial for cell adhesion, bidirectional mechanical and biochemical signaling (mechanotransduction), migration, and tissue organization[7][8]. Integrins anchor the cell cytoskeleton to the ECM and, together with other receptors (such as syndecans and discoidin domain receptors), regulate pathways involved in proliferation, survival, differentiation, and movement[2][3][5]. Dysregulation at the cell–ECM interface is implicated in cancer metastasis, fibrosis, chronic inflammation, wound healing defects, and cardiovascular disease, largely through abnormal signal transduction and ECM remodeling[2][4][7]. While integrins and their associated adhesion complexes are frequent drug targets, the interface itself is not a single discrete molecule and should not be considered a canonical therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cell-extracellular matrix interface.